ArticleAging medicine (Milton (N.S.W))2025
Genetically Predicted 1400 Blood Metabolites in Relation to Risk of Prostate Cancer: A Mendelian Randomization Study.
Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Metabolic dysregulation is common in cancer, yet evidence linking circulating metabolites to causal relationships in prostate cancer (PCa) is lacking. We performed a Mendelian randomization analysis utilizing 1400 blood metabolites to evaluate their roles in PCa. Methods: Exposure data from genome-wide association studies (GWAS) was extracted from metabolite level GWAS involving 462,933 individuals of European descent. GWAS data for PCa were obtained from the UK Biobank (UKB) database (79,148 cases, 61,106 controls) for a two-sample Mendelian randomization (MR) preliminary analysis, where we investigated potential causal relationships between 1400 metabolites and PCa. Inverse variance weighting (IVW) was the primary method for causal analysis, with MR-Egger and weighted median as supplementary analyses to enhance robustness. Sensitivity analyses including Cochran Results: Our findings revealed significant associations between two metabolites and prostate cancer: Cysteinylglycine disulfide levels (OR: 0.999, 95% CI: 0.998-0.999, Conclusions: Our results suggest that Cysteinylglycine disulfide levels may have a causal relationship with increased PCa risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.